Iterum Therapeutics, which is developing oral and IV antibiotics for urinary tract infections and intra-abdominal infections, filed on Tuesday with the SEC to raise up to $92 million in an initial public offering.
The Dublin, Ireland-based company was founded in 2015 and booked $0.5 million in revenue for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol ITRM. Iterum Therapeutics filed confidentially on February 2, 2018. Leerink Partners and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
